Analysts expect Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) to report $-0.13 EPS on December, 13.They anticipate $0.18 EPS change or 58.06% from last quarter’s $-0.31 EPS. After having $-0.07 EPS previously, Arrowhead Pharmaceuticals, Inc.’s analysts see 85.71% EPS growth. The stock decreased 9.00% or $0.35 during the last trading session, reaching $3.54. About 5.15 million shares traded or 376.19% up from the average. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has declined 67.27% since November 30, 2016 and is downtrending. It has underperformed by 83.97% the S&P500.
Mutual Of America Capital Management Llc increased Sempra Energy (SRE) stake by 10.44% reported in 2017Q2 SEC filing. Mutual Of America Capital Management Llc acquired 5,476 shares as Sempra Energy (SRE)’s stock rose 5.34%. The Mutual Of America Capital Management Llc holds 57,950 shares with $6.53M value, up from 52,474 last quarter. Sempra Energy now has $30.22B valuation. The stock increased 0.57% or $0.68 during the last trading session, reaching $120.26. About 1.05 million shares traded. Sempra Energy (NYSE:SRE) has risen 8.27% since November 30, 2016 and is uptrending. It has underperformed by 8.43% the S&P500.
Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. The company has market cap of $264.69 million. The Company’s pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. It currently has negative earnings. The firm also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma.
Among 6 analysts covering Arrowhead Research Corp (NASDAQ:ARWR), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Arrowhead Research Corp had 18 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was downgraded by William Blair to “Mkt Perform” on Wednesday, November 30. RBC Capital Markets maintained the shares of ARWR in report on Wednesday, August 5 with “Hold” rating. The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has “Hold” rating given on Monday, June 26 by Jefferies. Chardan Capital Markets initiated the shares of ARWR in report on Thursday, May 19 with “Buy” rating. The firm has “Buy” rating by Piper Jaffray given on Monday, November 27. On Friday, September 25 the stock rating was maintained by Piper Jaffray with “Overweight”. William Blair upgraded Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) on Monday, September 18 to “Outperform” rating. PiperJaffray downgraded the stock to “Neutral” rating in Wednesday, November 30 report. The firm has “Buy” rating by Chardan Capital Markets given on Thursday, November 10. The firm has “Buy” rating by Cantor Fitzgerald given on Friday, August 19.
Mutual Of America Capital Management Llc decreased Nvidia Corporation (NASDAQ:NVDA) stake by 4,361 shares to 72,799 valued at $10.52M in 2017Q2. It also reduced Globant Sa stake by 26,304 shares and now owns 57,765 shares. Fifth Third Bancorp (NASDAQ:FITB) was reduced too.
Among 8 analysts covering Sempra Energy (NYSE:SRE), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Sempra Energy had 16 analyst reports since September 15, 2015 according to SRatingsIntel. The rating was maintained by JP Morgan on Thursday, October 12 with “Neutral”. The stock has “Outperform” rating by RBC Capital Markets on Monday, January 25. On Sunday, October 1 the stock rating was maintained by RBC Capital Markets with “Buy”. On Thursday, June 8 the stock rating was downgraded by Barclays Capital to “Equal-Weight”. On Thursday, August 10 the stock rating was maintained by Morgan Stanley with “Overweight”. The firm earned “Buy” rating on Sunday, August 27 by RBC Capital Markets. The firm earned “Outperform” rating on Tuesday, October 10 by Wells Fargo. The stock has “Buy” rating by Goldman Sachs on Wednesday, October 11. BMO Capital Markets maintained it with “Hold” rating and $11800 target in Friday, August 4 report. The stock has “Buy” rating by RBC Capital Markets on Sunday, July 23.
The post EPS for Arrowhead Pharmaceuticals, Inc. (ARWR) Expected At $-0.13; Mutual Of America Capital Management Has Lifted Sempra Energy (SRE) Position By $613,312 appeared first on Stock Market News | HillCountryTimes | Get it Today.
from
https://www.hillcountrytimes.com/2017/11/30/eps-for-arrowhead-pharmaceuticals-inc-arwr-expected-at-0-13-mutual-of-america-capital-management-has-lifted-sempra-energy-sre-position-by-613312/
No comments:
Post a Comment